Standout Papers

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diab... 2017 2026 2020 2023 469
  1. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (2017)
    Christopher Sorli, Shin‐ichi Harashima et al. The Lancet Diabetes & Endocrinology

Immediate Impact

1 by Nobel laureates 10 from Science/Nature 75 standout
Sub-graph 1 of 22

Citing Papers

Tirzepatide for Obesity Treatment and Diabetes Prevention
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
2 intermediate papers

Works of Christopher Sorli being referenced

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
2017 Standout
New Developments in Insulin Therapy for Type 2 Diabetes
2014

Author Peers

Author Last Decade Papers Cites
Christopher Sorli 790 429 409 28 1.1k
Antoine Makdissi 996 430 261 31 1.3k
Shizuka Kaneko 799 278 385 22 962
Phil Ambery 856 387 438 54 1.3k
Lisbeth V. Jacobsen 935 363 384 24 1.2k
Santiago Tofé 987 330 467 40 1.2k
Mary Beth DeYoung 623 384 656 23 1.4k
Christian Friedrich 532 335 461 32 1.1k
Ericka Moerman 664 686 395 18 1.2k
Moufida Ben Nasr 444 461 279 35 1.1k
R A Jackson 553 318 277 25 1.2k

All Works

Loading papers...

Rankless by CCL
2026